3K3A-APC is under clinical development by ZZ Biotech and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 3K3A-APC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
3K3A-APC is under development for the treatment of Alzheimer’s disease, acute ischemic stroke, amyotrophic lateral sclerosis (ALS), neurotrauma, diabetic foot ulcers, chronic wounds and sepsis. The drug candidate is administered through intravenous route. It is a recombinant genetically engineered variant of the naturally occurring activated protein C (APC). It was also under development for the treatment of septic shock.
ZZ Biotech overview
ZZ Biotech is a pharmaceutical and healthcare company focused on the development of biologic treatments for ischemic stroke and other neurological diseases. The company’s lead product includes 3K3A-APC, a genetically engineered recombinant human activated protein C (APC) that reduces anticoagulant activity, which minimizes the risk of bleeding and also maintains cell-protective. In addition, it is also used as anti-inflammatory activities indicated for the treatment acute ischemic stroke and diabetic foot ulcers. The company has operations in Sydney, Australia. ZZ Biotech is headquartered in Houston, Texas, the US.
For a complete picture of 3K3A-APC’s drug-specific PTSR and LoA scores, buy the report here.